We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CZNC:NASDAQCitizens & Northern Corp Analysis

Data as of 2026-06-03 - not real-time

$20.39

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Citizens & Northern Corp (CZNC) is trading at $20.39, just above the computed support of $20.20 and below both its 20‑day ($20.99) and 50‑day ($22.11) simple moving averages, indicating a short‑term downtrend that may be stabilizing. The 14‑day RSI of 34.6 points to modest oversold pressure, while the MACD shows a bullish crossover (histogram +0.02) that could seed a modest rebound. Volatility is elevated at roughly 26% over the past 30 days, but beta is low‑to‑moderate (≈0.44‑0.61), suggesting market moves have limited impact on the stock.
Fundamentally, the bank faces a 13.8% revenue contraction and thin operating margins (1.45%), yet it delivers an attractive dividend yield of 5.35% backed by a payout ratio above 100%, raising sustainability concerns. The DCF‑derived fair value of $12.43 is well below the current price, and the trailing P/E of 19 exceeds the industry average of 16, signaling that the market may be overvaluing the stock relative to its earnings and intrinsic worth. These mixed signals imply limited upside potential in the near term, with dividend income being the primary attraction, albeit on shaky footing.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support and just below short‑term SMAs
  • Bullish MACD crossover suggesting limited upside
  • Elevated 30‑day volatility but low beta

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Negative revenue growth and thin margins
  • High dividend yield offset by unsustainable payout ratio
  • Current price still above DCF fair value

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Persistent earnings pressure and revenue decline
  • Overvaluation relative to intrinsic value and industry peers
  • Potential dividend cuts if payout remains above earnings

Key Metrics & Analysis

Financial Health

Revenue Growth-13.80%
Profit Margin15.41%
P/E Ratio19.1
ROE5.64%
ROA0.60%
P/B Ratio1.1
Op. Cash Flow$39.1M
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI34.6
Support$20.20
Resistance$22.10
MA 20$20.99
MA 50$22.11
MA 200$21.11
MACDBullish
VolumeStable
Fear & Greed Index92.55

Valuation

Fair Value$12.43
Target Price$24.00
Upside/Downside17.73%
GradeOvervalued
TypeValue
Dividend Yield5.35%

Risk Assessment

Beta0.61
Volatility26.47%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.